13D Filing: Jeffrey Alan Berg and Ntn Buzztime Inc (NYSEMKT:NTN)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Matador Capital Partners 0 423,000 0 423,000 423,000 17.03%
BFK Investments 0 423,000 0 423,000 423,000 17.03%
Jeffrey A. Berg 10,600 10,600 423,000 433,600 17.46%

Page 1 of 8 – SEC Filing

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

SCHEDULE
13D

 

Under
the Securities Exchange Act of 1934

(Amendment
No. 9)

 

NTN
Buzztime, Inc.

(Name
of Issuer)

 

Common
Stock, par value $.005 per share

(Title
of Class of Securities)

 

629410606

(CUSIP
Number)

 

Jeffrey
A. Berg

603
N. Indian River Drive

Suite
300

Ft.
Pierce, FL 34950

(760)
438-7400

(Name,
Address and Telephone Number of Person

Authorized
to Receive Notices and Communications)

 

March
31, 2017

(Date
of Event Which Requires Filing of this Statement)

 

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box. [  ]

 

Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
section 240.13d-7 for other parties to whom copies are to be sent.

 

*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.

 

The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).

 

Potential
persons who are to respond to the collection of information contained in this form are not required to respond unless the form
displays a currently valid OMB control number.

 

 

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 2 of 8 – SEC Filing

 

 

1. Names
of Reporting Persons
 
     
  Matador
Capital Partners, L.P.
 
     
     
2. Check
the Appropriate Box if a Member of a Group (See Instructions)
 
  (a) [  ]
  (b) [X]
     
     
3. SEC
Use Only
 
     
     
4. Source
of Funds (See Instructions)
WC
     
     
5. Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ____
 
     
     
6. Citizenship
or Place of Organization
Delaware
     

 

Number
of

Shares

Beneficially

Owned
by

Each
Reporting

Person
With

7. Sole
Voting Power

0

 

8. Sh1red Voting Power 423,000

 

9.

Sole
Dispositive Power

 

0
10. Shared Dispositive
Power
423,000
 

 

11. Aggregate
Amount Beneficially Owned by Each Reporting Person

423,000

   
     
12.

Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions

 

_______
     
13.

Percent
of Class Represented by Amount in Row (11)

 

17.03%
     
14.

Type
of Reporting Person (See Instructions)

 

PN

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 3 of 8 – SEC Filing

 

1. Names
of Reporting Persons  
 
     
  BFK
Investments LLC
 
   
     
2. Check
the Appropriate Box if a Member of a Group (See Instructions
  (a) [  ]
 

(b)

 

[X]
     
3.

SEC
Use Only

 

 
     
4. Source
of Funds (See Instructions)  
AF
     
     
5.

Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)____

 

 
     
6.

Citizenship
or Place of Organization  

 

Florida

 

 

Number
of

Shares

Beneficially

Owned
by

Each
Reporting

Person
With

7. Sole
Voting Power
0
   
8. Shared
Voting Power  

423,000

 
9. Sole
Dispositive Power  
0
     
10. Shared
Dispositive Power
423,000
 

 

11.

Aggregate
Amount Beneficially Owned by Each Reporting Person

 

423,000
     
12. Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
________

 

     
13. Percent
of Class Represented by Amount in Row (11)
17.03%

 

     
14.

Type
of Reporting Person (See Instructions)

 

OO

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 4 of 8 – SEC Filing

 

1. Names
of Reporting Persons  
 
     
 

Jeffrey
A. Berg

 

 
     
2. Check
the Appropriate Box if a Member of a Group (See Instructions)
 
  (a) [  ]
 

(b)

 

[X]
     
3. SEC
Use Only
 
     
     
4. Source
of Funds (See Instructions)  
AF,
PF
     
     
5. Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ____
 
   
     
6.

Citizenship
or Place of Organization

 

U.S.

 

Number
of

Shares

Beneficially

Owned
by

Each
Reporting

Person
With

7. Sole
Voting Power  
10,600
     
8. Shared
Voting Power  
423,000
     
9. Sole
Dispositive Power  
10,600
     
10. Shared
Dispositive Power
423,000
   

 

11. Aggregate
Amount Beneficially Owned by Each Reporting Person
433,600
     
     
12.

Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

______
     
13. Percent
of Class Represented by Amount in Row (11)

17.46%

 

     
14. Type
of Reporting Person (See Instructions)
IN,
HC
   

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 5 of 8 – SEC Filing

 

Pursuant
to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 9 to Schedule 13D (this “Amendment
No. 9
”) amends the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”)
on September 29, 2008 (the “Original Schedule 13D”), as amended by the amendments thereto previously filed
with the SEC on the dates indicated below (the Original Schedule 13D, as amended through and including this Amendment No. 9 are
collectively referred to herein as the “Schedule 13D”):

 

Amendment
No.
  Filing
Date
1   December
19, 2008
2   January
14, 2011
3   January
14, 2011
4   March
7, 2012
5   September
13, 2012
6   December
27, 2012
7   April
21, 2014
8   November
4, 2016

 

The
Schedule 13D relates to the shares of Common Stock (the “Stock”) of NTN Buzztime, Inc. (the “Issuer”)
owned by Matador Capital Partners, L.P. (the “Fund”), BFK Investments LLC (“BFK”), the general
partner of the Fund, and Jeffrey A. Berg, the Managing Member of BFK. The Fund, BFK and Jeffrey A. Berg are collectively referred
to herein as the “Reporting Persons”. Except as specifically amended by this Amendment No. 9, items in the
Schedule 13D are unchanged.

 

This
Amendment No. 9 reports a decrease in the Reporting Persons’ percentage of beneficial ownership of the outstanding shares
of Stock since the date the Reporting Persons’ last filing on Schedule 13D as a result of the Issuer’s issuance of
200,000 shares of Stock in connection with a registered direct offering that the Issuer completed on March 31, 2017 (the “March
2017 Offering
”). None of the Reporting Persons acquired any shares of Stock in the March 2017 Offering.

 

Information
in this Amendment No. 9 with respect to each of the Reporting Persons is given solely by that particular Reporting Person, and
none of the other Reporting Persons has any responsibility for the accuracy or completeness of information with respect to any
other Reporting Person. Capitalized terms used herein that are not defined herein have the meanings ascribed to them in the Schedule
13D.

 

Item
3. Source and Amount of Funds or Other Consideration

 

The
information provided in Item 5 of this Amendment No. 9 is incorporated by reference to this Item 3.

 

Item
3 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

 

In
November 2016, the Fund purchased 5,620 shares of Stock reported in Item 5 of this Amendment No. 9 using its working capital.
The aggregate purchase price was $40,679.

 

Item
5. Interest in Securities of the Issuer

 

Paragraphs
(a), (b) and (d) of Item 5 of the Schedule 13D are hereby amended by replacing them in their entirety with the following:

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 6 of 8 – SEC Filing

 

(a),
(b) & (d): Each Reporting Person’s beneficial ownership of the Stock on the date of this Amendment No. 9 is reflected
on that Reporting Person’s cover page of this Amendment No.9. The percentage of shares owned by the Reporting Persons is
based upon 2,483,892 shares of Stock outstanding, which is the number of shares outstanding immediately after the March 2017 Offering,
as reported in the Issuer’s filings with the SEC. BFK is a limited liability company and serves as the general partner of
the Fund with the power to invest in, vote and dispose of the Stock on behalf the Fund. The Fund has the right to receive or the
power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Only Mr. Berg as a limited partner
in the Fund individually has an interest through the Fund in more than 5% of the outstanding Stock. Mr. Berg is the Managing Member
of BFK and controls the investment decisions of BFK and the Fund. The Reporting Persons are filing the Schedule 13D jointly, but
not as members of a group, and each of them expressly disclaims membership in a group. Each of BFK and Mr. Berg disclaims beneficial
ownership of the Stock except to the extent of that Reporting Person’s pecuniary interest therein. In addition, the filing
of the Schedule 13D on behalf of the Fund should not be construed as an admission that any of the other Reporting Persons is,
and each of them disclaims that it is, the beneficial owner, as defined in Rule 13d-3 under the Securities Exchange Act of 1934,
of any of the Stock covered by the Schedule 13D.

 

Paragraph
(c) of Item 5 of the Schedule 13D is hereby amended by the addition of the following:

 

(c)
The following sets forth all transactions with respect to Shares effected by the Reporting Persons since their last filing on
Schedule 13D: In November 2016, the Fund purchased 5,620 shares of Stock using its working capital, the aggregate purchase price
for which was $40,679. Except as otherwise noted above, all such transactions were purchases of Shares effected in the open market,
and the purchase price includes commissions paid.

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 7 of 8 – SEC Filing

 

SIGNATURE

 

After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.

 

Dated:
March 31, 2017
  MATADOR
CAPITAL PARTNERS, L.P.
       
     
  By:     Name: BFK
Investments LLC
    Title: General
Partner
       
  By:  /s/ Jeffrey A. Berg
    Name: Jeffrey
A. Berg
    Title: Managing
Member
       
Dated:
March 31, 2017
  BFK
INVESTMENTS LLC
       
  By: /s/ Jeffrey A. Berg
    Name: Jeffrey
A. Berg
    Title: Managing
Member

 

Dated:
March 31, 2017
JEFFREY
A. BERG
   
  /s/
Jeffrey A. Berg
  Jeffrey
A. Berg

 

The
original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner
of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the
statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated
by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)

Page 8 of 8 – SEC Filing

 

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)